This morning Lilly reported full year results while BD reported yesterday. When it comes to diabetes both companies are performing very well. Which makes one wonder why both companies want to venture outside their core competency and enter the insulin pump market. BD’s move into this area is more surprising than Lilly’s as BD owns the needle and syringe area and each time they have strayed from this area it has not ended well.
As we have noted before we can somewhat understand Lilly’s move into the pump space as if done well it could help sell . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.